Tech Company Financing Transactions
Ansa Biotechnologies Funding Round
Cerberus Capital Management, AIM13 and Altitude Life Science Ventures joined a $54.4 million Series B funding round for Ansa Biotechnologies. The round was announced on 10/1/2025.
Transaction Overview
Company Name
Announced On
10/1/2025
Transaction Type
Venture Equity
Amount
$54,400,000
Round
Series B
Investors
Proceeds Purpose
The proceeds from this financing will enable Ansa to expand its U.S.-based manufacturing capacity, enhance its focus on customer experience, and continue to advance strategic relationships and technological innovation.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
1198 65th Street Suite 250
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Arlow
Chief Financial Officer
Aviad Haimi-Cohen
Chief Technical Officer
Sebastian Palluk
VP - Engineering
Jared Ellefson
VP - Product Management
George McArthur
Browse more venture capital transactions:
Prev: 10/1/2025: SeaBeLife venture capital transaction
Next: 10/1/2025: Cerebras Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs